Boston Scientific to Release Long-Term Clinical Trial Results on Market-
Leading TAXUS® Express2™
Coronary Stent System at TCT 2005
OLYMPIA and BEACH Data Also to be Released
NATICK, Mass., Oct. 10 -- Boston Scientific Corporation (NYSE: BSX - News)
today announced the schedule of the Company's major events and press announcements
at the Transcatheter Cardiovascular Therapeutics (TCT) conference, which runs
from October 16 to 21 in Washington, D.C. Boston Scientific will be announcing
long-term efficacy data on its TAXUS® Express2™
paclitaxel-eluting stent system, including results from the TAXUS I, II, IV and
VI clinical trials, as well as data from the ARRIVE, MILESTONE II and OLYMPIA "real-world" registries.
Together, these studies represent more than 38,000 patients. The TAXUS clinical
trials represent the largest body of randomized drug-eluting stent data available
today. Boston Scientific's participation in TCT 2005 will include 16 clinical
abstracts, 20 additional scientific presentations and 2 educational symposia.
The Company will also highlight its new IVUS diagnostic technology, the iLab(TM)
Ultrasound Imaging System.
"The data we will present at TCT continues to reinforce the strengths that make TAXUS the leader in the worldwide drug-eluting stent market: safety, efficacy and deliverability," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "The long-term data from our TAXUS program shows a sustained efficacy benefit out to four years and an established 'real-world' safety record. The quality and rigor of our clinical trials has also raised the bar regarding the use of evidence-based medicine in determining treatment decisions."
Schedule of Events
Monday, October 17 (all times are ET)
- Carotid Stenting Results. On Monday, Boston Scientific will issue a
press release containing important updates within its Carotid Artery
Stenting (CAS) program. Data will be presented from the Company's
BEACH clinical trial, designed to evaluate the benefits of CAS in
conjunction with embolic protection for the treatment of carotid artery
disease. A separate abstract will highlight resource use data captured
during the BEACH study in order to provide accurate cost information
for improved reimbursement planning.
-
Symposium on Carotid Artery Stenting. From 8:00-10:00 p.m., the
Company will host an evening symposium entitled "Carotid Artery
Stenting: Moving Beyond BEACH" moderated by Sriram Iyer, M.D., in the
Grand Ballroom of the Renaissance Hotel, located at 999 Ninth Street,
NW. Topics will include one-year data from the BEACH and CABERNET
clinical trials, carotid stenting in octogenarians, bilateral disease,
embolic protection and risk stratification. Speakers will include
Sriram Iyer, M.D., L. Nelson Hopkins, M.D., Barry Katzen, M.D.,
Subbarao Myla, M.D. and Michael Jaff, M.D.
Tuesday, October 18
- TAXUS Long-Term Results. The Company will announce follow-up
data on long-term safety and efficacy from four of its TAXUS
paclitaxel-eluting
stent clinical trials. Results will be presented from TAXUS I (up
to four years), TAXUS II (up to three years), TAXUS IV (up to three
years), and TAXUS VI (up to two years). The Company will issue a
press
release summarizing data from all four clinical trials.
- Analyst Meeting.
At 5:30 p.m., the Company will host an analyst meeting in Congressional
Hall A&B of the Renaissance Hotel. The
meeting is open to the media. This meeting is being webcast and can
be accessed at Boston Scientific's website,
http://www.bostonscientific.com. Please visit the website for details
on how to access the webcast. To ensure a timely connection to the
webcast it is recommended that users register at least 15 minutes
before the webcast begins. A replay of the webcast will be archived
and available in the Webcast and Archives section of the Investor
Relations site at http://www.bostonscientific.com.
- Symposium on Drug-Eluting
Stents. From 8:00-10:00 p.m., the Company will host an evening
symposium entitled "Drug-Eluting
Stents 2005: Challenges Overcome, Frontiers Yet to Conquer" chaired
by Gregg W. Stone, M.D. and Sigmund Silber, M.D., in the Grand
Ballroom of the
Renaissance Hotel. Topics will include durability of DES trial
results, "real-world" studies, diabetes as a risk factor for
restenosis, and evidence based medicine. Speakers will include Gregg
Stone, M.D., Sigmund Silber, M.D., Donald Baim, M.D., Keith Dawkins,
M.D., Stephen Ellis, M.D., John Lasala, M.D., and Patrick Serruys,
M.D.
Wednesday, October 19
- Evidence-Based Medicine. On Wednesday, the Company will
issue a press release highlighting the importance of pursuing
evidence-based
medicine
through the increased use of randomized controlled clinical trials.
The release will feature comments from a symposium presentation titled "Evidence Based Medicine and Best Practices with DES",
which will highlight the need for large scale, multi-center, randomized,
controlled trials with a primary clinical endpoint.
Thursday, October 20
- OLYMPIA Registry. On Thursday, the Company will issue a press
release announcing 30-day safety data from its OLYMPIA registry,
which is
designed to collect and analyze "real-world" clinical outcomes data
using Boston Scientific's next-generation TAXUS® Liberte(TM)
paclitaxel-eluting stent system in the treatment of patients with
coronary artery disease.
- DES Outcomes in Diabetic Patients. On Thursday,
the Company will issue a press release announcing nine-month sub-population
data from
its
TAXUS V clinical trial, detailing outcomes for its TAXUS Express2
paclitaxel-eluting stent in the treatment of diabetic patients,
particularly higher-risk, insulin-requiring diabetics.
New Technology Demonstration
- iLab(TM) Ultrasound Imaging System: Boston Scientific's
booth (No. 616) will feature a "virtual cath lab", showcasing
the Company's new iLab Ultrasound Imaging System -- a completely
functional IVUS system
designed to be installed into a cath lab. Clinical specialists
will be present to demonstrate the technology, which includes
a physician
tableside controller and a touch screen interface. iLab is FDA
approved and will be featured in several live cases during TCT.
Boston Scientific is a worldwide developer, manufacturer and marketer
of medical devices whose products are used in a broad range of interventional
medical specialties. For more information, please visit: http://www.bostonscientific.com.
This press release contains forward-looking statements. The Company
wishes to caution the reader of this press release that actual results
may differ from those discussed in the forward-looking statements
and may be adversely affected by, among other things, risks associated
with
clinical trials, the regulatory approval process, reimbursement
policies, commercialization of new technologies, litigation, the
Company's overall
business strategy and other factors described in the Company's filings
with the Securities and Exchange Commission.
CONTACT:
Milan Kofol
508-650-8569
Investor Relations
Boston Scientific Corporation
Paul Donovan
508-650-8541
Media Relations
Boston Scientific Corporation
Source: Boston Scientific Corporation
|
